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Introduction/Abstract
The liver plays critical roles in both homeostasis and pathology. It is the major site of drug 
metabolism in the body and, as such, a common target for drug-induced toxicity and is susceptible 
to a wide range of diseases. In contrast to other solid organs, the liver possesses the unique ability 
to regenerate. The physiological importance and plasticity of this organ make it a crucial system of 
study to better understand human physiology, disease, and response to exogenous compounds.
The purpose of this review is to inform the reader of the significance and available methods for 
replicating human liver physiology and pathology ex vivo. First, the physiologic roles of the liver 
and its cellular constituents will be discussed. Second, we will discuss the need for developing an 
ex vivo liver system. Third, the advantages and disadvantages of different cell sources used to 
populate the system will be mentioned. Fourth, the benefits of currently employed ex vivo liver 
culture systems (both commercially available and used in research laboratories) will be discussed. 
Finally, future directions to advance these systems, including complexing liver culture systems 
with other organ-based culture systems (“organ chips”), will be proposed.
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Physiology
The liver is a complex organ that is integral to a multitude of whole body functions and is 
extensively reviewed in standard medical textbooks. For the purposes of this review, a few 
salient aspects are emphasized. The liver is organized into lobules, functional units of the 
liver, which are subsequently organized into larger lobes. Lobules consist of multiple hepatic 
sinusoids, whose structure is illustrated in Figure 1A. The flow of blood from the portal triad 
to the central vein contributes to a zonation based on decreasing oxygen tension. This affects 
both the parenchymal (hepatocytes) and non-parenchymal cells (NPC) that will be discussed 
herein.
The parenchymal cells, mainly hepatocytes, comprise 60% of the cell population and are 
responsible for the liver’s metabolic activity (including the cytochrome P450 (CYP450) 
isoforms), the production and release of acute phase proteins, production of plasma proteins 
(such as albumin and clotting factors), and the integration of various components of glucose, 
lipid, nitrogen, and oxidative metabolism1,2. These hepatocytes mature postnatally, causing 
different CYP450 isoforms and assemblies thereof to be expressed in fetal, neonatal and 
adult hepatocytes3. For example, CYP3A7 is very highly expressed in fetal hepatocytes, 
whereas this isoform is replaced by CYP3A4 expression in adult hepatocytes. Moreover, 
pediatric hepatocytes typically exhibit increased clearance of CYP450-metabolized drugs as 
compared to adult hepatocytes4, despite no differences in intrinsic CYP450 expression 
between the two cell sources5. Thus, hepatocyte functioning is key to any ex vivo system 
that replicates the in vivo liver.
Oxygen tension plays an important role in regulating liver zonation and functionality, with 
the liver uniquely receiving both arterial (hepatic artery, ~25%) and venous (portal 
circulation, ~75%) blood. The partial pressure of oxygen drops as one progresses across the 
liver sinusoid, the functional unit of the liver, from periportal to perivenous hepatocytes6. 
This oxygen differential regulates the response of the liver to metabolic and toxic stimuli by 
facilitating differential metabolism, termed “liver zonation.” For example, the relatively 
hypoxic perivenous hepatocytes are responsible for the majority of substrate metabolism 
through the CYP450 system whereas the relatively oxygen-rich periportal hepatocytes boast 
mainly oxidative metabolic functions6. Liver zonation is also observed in in vitro cultures7,8. 
Thus, the organization of the parenchyma motivates careful engineering to replicate hepatic 
function and toxicity and capture the full panoply seen in vivo.
Blood flow carried through vessels lined by the fenestrated endothelium of the sinusoids is 
imperative for liver functions. Hepatic blood flow dictates the metabolic zonation of the 
liver6 and alterations in flow can reduce liver function and drug clearance9. Blood flow 
carries oxygen, nutrients, and chemicals that are distributed to the liver tissue. In the absence 
of adequate blood flow, these factors are consumed by the proximate cells and do not reach 
more distant populations. Reciprocally, juxtavascular cells can contribute factors to the 
circulation. Locally, the potency of hepatocyte-secreted factors is a function of the blood-to-
cell volume ratio, which is approximately 20.5 mL blood per mL tissue for healthy adult 
livers10. Assuming a hepatocyte volume of 3.4 pL11, this corresponds to roughly 14 million 
hepatocytes being supplied by 1 mL of blood. This consideration is particularly important 
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for in vitro and ex vivo culture systems, as media flow is used by some to model in vivo 
blood flow (see “Engineered Culture Systems”).
The non-parenchymal cells (NPC) compose the remaining 40% of the cell population and 
play a significant role in tissue architecture and in mediating responses of the tissue to 
metabolic and toxic stimuli, as well as supporting the hepatocyte function2,12. These cell 
types include liver sinusoidal endothelial cells (LSECs), Kupffer cells (KCs), hepatic stellate 
cells (HSCs), and pit cells (natural killer cells, NKs). Inclusion of NPCs in hepatocyte 
culture systems has shown beneficial effects. For example, 3-dimensional (3D) liver tissue 
models show increased hepatocyte functions when nonparenchymal cells are incorporated13. 
Additionally, KCs play a significant role in the response of the liver to injury through the 
production of cytokines and reactive oxygen species14. Moreover, HSCs respond to injury 
both by adopting a myofibroblast phenotype that remodels the liver extracellular matrix15 
and increasing the CYP450 activity of hepatocytes16. Finally, LSEC proliferation in 
response to injury has been suggested to aid the liver’s potent regenerative capacity17. Thus, 
the NPCs complement the synthetic and metabolic functions of hepatocytes by contributing 
pro-regenerative, pro-inflammatory, and pro-fibrotic stimuli.
Modeling the Liver Microenvironment
Current preclinical models for hepatotoxicity involve human cell culture and animal models. 
Recently, efforts to develop ex vivo hepatic culture systems, “liver-on-a-chip,” have been 
undertaken by many research groups and biotech companies due to the liver’s capacity for 
drug metabolism, excretion, vulnerability to drug-induced damage, and as a primary organ 
in many diseases. Drug-induced liver injury remains a major reason for drugs being 
withdrawn from the market, and causes both morbidity and mortality for patients. 
Importantly, humans metabolize and respond to agents differently from other mammals; to 
the point, most all species present unique xenobiotic handling18. In fact, one-third of 
toxicities observed in humans are not predicted in any of the species commonly employed 
for drug safety testing19, possibly due to their failure to model reactive metabolites 
generated through human-specific metabolic pathways20. Moreover, individual animal 
models have a success rate of as low as 40% in predicting hepatotoxic compounds21, 
resulting in 26% of clinical trial failures being due to hepatotoxicity22.
Current liver tissue culture systems exist on a spectrum of complexity. Historic hepatocyte 
culture systems involved collagen-sandwich culture or 2D Micro-Patterned Co-culture 
(MPCC) systems using primary rat hepatocytes and 3T3-J2 fibroblasts. Systems have 
progressed to include 3D static spheroid models and perfusion culture devices, which 
introduce nutrient and oxygen gradients and shear stress that are important for hepatocyte 
functions23. The systems discussed below offer distinct advantages and disadvantages for 
investigating the response of hepatic micro-tissues to different drugs and other stimuli.
Cell Sourcing
The complex physiology of the liver and need for its accurate representation in engineered 
systems requires careful selection of cell type(s) and their origin. As previously discussed, 
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hepatic tissue is composed of hepatocytes (60% of liver cells) and a complex complement of 
NPCs (40% of liver cells). Integration of both cell fractions is often needed to adequately 
reflect pharmacokinetics, pharmacodynamics, toxicity of drugs, and liver disease 
progression, given the intercommunication between the different liver cell types. Four 
sources of hepatocytes will be discussed: primary human cells, primary animal cells, 
immortalized human cell lines, and pluripotent stem cells. Each of these cell sources has its 
advantages and disadvantages, and each will be discussed below. A qualitative summary of 
cell selection parameters can be seen in Table 1.
Primary human hepatocytes
Functional primary human hepatocytes obtained through collagenase perfusion and 
dissociation have been the gold standard in drug discovery for 25 years due to their ability to 
most accurately reflect in vivo metabolism and toxicity24–26. Primary human hepatocytes 
have been isolated from livers with benign (processes not affecting the hepatocytes) and 
hepatocyte-specific pathologies. Some examples include end stage primary biliary cirrhosis 
(PBC), primary sclerosing cholangitis (PSC), alcoholic liver disease (ALD), and resections 
for colorectal metastases or benign growths27. Several groups have found patient-specific 
factors to play a role in the yield of hepatocytes during isolation or in their functionality. 
While patient gender and type of disease had no effect on hepatocyte yield or 
functionality28,29, cholestasis (signified by elevated gamma glutamyl transferase level – 
GGT)30,31, severe steatosis31,32, and older age29,31,33,34 negatively influenced isolation 
outcomes. Although some patients have been exposed to chemotherapy, hepatocyte function 
and viability are not altered35. While an ideal source, limited availability of cells and 
reliance on patient surgeries are major reasons why primary hepatocytes are not more 
commonly used. Moreover, many donors are pediatric patients, whose hepatocytes may have 
metabolic dysfunction or exhibit differential clearance when compared to adult human 
hepatocytes (see “Physiology”).
Advances in cryopreservation have allowed for easier distribution and commercialization of 
primary human hepatocytes. Previous work has demonstrated cryopreserved primary human 
hepatocytes to still exhibit 94% of the clearance of model drugs (e.g. diclofenac) after 1 year 
in liquid nitrogen, as compared to freshly isolated human hepatocytes36. With proper 
cryopreservation, viabilities >90% can be achieved37. Additionally, minimal changes in 
metabolic functions have been demonstrated even after 14 years in liquid nitrogen38. While 
cryopreserved primary human hepatocytes exhibit high viability and comparable CYP450 
activity to fresh cells, they exhibit suboptimal attachment to extracellular matrix molecules, 
due to downregulation and degradation of the adhesion molecules β1-integrin and E-
cadherin respectively during cryopreservation39. Additionally, decreased expression of 
uptake transporters such as OATP (organic anion-transporting polypeptide) and NTCP 
(sodium-taurocholate co-transporting polypeptide) family members results in under-
prediction of drug clearance rates40. Finally, high viability methods often involve 
centrifugation to remove dead and damaged hepatocytes, which also reduces the cell yield.
Cryopreserved primary human hepatocytes have been used in numerous studies to 
investigate CYP450 induction41, drug clearance42, and hepatobiliary transport43. In contrast 
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to human hepatic cell lines or animal primary cells, cryopreserved primary human 
hepatocytes can probe the influence of genetic background on hepatocyte metabolism or 
drug clearance. For example, a collection of cryopreserved hepatocytes from 64 donors has 
been used to investigate gender-specific activities of CYP450 isoforms in vitro, which 
corroborated with in vivo findings, namely a higher expression of CYP3A4, the most 
dominant human isoform, in females44. Thus, while human cell lines and animal hepatocytes 
are more accessible, primary human hepatocytes will likely continue to play an important 
role in drug development due to their ability to most effectively reflect in vivo metabolism, 
clearance, and response to toxins by patients.
Animal-derived hepatocytes
Animal-based testing has formed the foundation for translating in vitro studies to clinical 
trials. Before moving to humans, the Federal Drug Administration (FDA) requires 
pharmacokinetic, toxicity, and efficacy studies in at least one rodent (mouse, rat) and one 
non-rodent (dog, rabbit) species. Such studies are designed to examine integrated organ 
responses and are able to suggest, at least initially, the influence of genetic diversity on drug 
responses45. Additionally, these species are readily commercially available, thus serving as 
sources of fresh primary cells. However, animal studies frequently do not elicit the 
pharmacokinetic behavior seen in humans due to species differences in drug metabolism and 
clearance, in particular differential CYP450 metabolic activity46,47. Differences in CYP450 
induction by model drugs between human and animal (rat, dog) are well established48. 
Improvements in predicting human-specific metabolism and clearance from animal studies 
have been made through retrospective analyses49. Yet, sourcing cells from animals may be 
cost prohibitive, ethically controversial, and futile if interspecies differences prevent human-
relevant data from being collected50. Moreover, since animal hepatocytes express different 
CYP450 isoforms than humans, extrapolating of gender-specific differences in drug 
metabolism is challenging51.
Human hepatic cell lines
Human hepatic cell lines, either cancer-derived or immortalized hepatocytes, can be 
effectively propagated in culture over multiple passages. Some of the most commonly used 
hepatic cell lines include HepG2, Huh7, Hep3B, and SK-Hep-1, all derived from 
hepatocellular carcinoma (HCC), and HepaRG, an HCC cell line that constitutes a mix of 
both hepatocytes and biliary-like cells52,53.
One issue with using human hepatic cell lines is that they exhibit lower and variable 
CYP450 expression than primary human hepatocytes53. For example, CYP3A4 is not 
expressed in HepG2 or Hep3B cells whereas CYP2D6 is expressed at less than 5% the level 
of primary human hepatocytes. Studies in HepG2 cells demonstrated that CYP450 
expression may also vary according to culture duration and passage number, some isoforms 
varying up to 200-fold across the first 10 passages54. Some cell lines hold more promising 
results. For example, induction of CYP450 enzymes and the drug transporter MDR1 was 
seen in a novel hepatic cell line, Fa2N-4, in response to rifampin treatment55.
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Another issue with human hepatic cell lines is that they exhibit reduced expression of both 
sinusoidal and canalicular transporters56. These transporters function to shuttle drug 
compounds from the blood to the bile canaliculi. While hydrophobic compounds can diffuse 
across the hepatocyte plasma membrane, hydrophilic compounds require active transport. 
Reduced transport activity and decreased CYP450-catalyzed metabolism may result in 
inaccurate pharmacokinetic and toxicity predictions.
The HepaRG cell line is a promising substitute for primary human hepatocytes. When 
seeded at a low density, HepaRG cells are capable of proliferating and differentiating to 
confluency to form colonies of hepatocytes surrounded by biliary epithelial cells that exhibit 
CYP450 expression levels comparable to primary human hepatocytes57. HepaRG cells have 
also been found to functionally express both sinusoidal and canalicular transporters58,59. 
Additionally, HepaRG cells can identify drugs likely to induce liver injury, albeit using 
doses up to 100-fold higher than would be seen clinically60. Moreover, HepaRG cells exhibit 
a more robust response to inflammatory stimuli (e.g. IL-6, TNFα) on liver drug metabolism 
and elimination than primary human hepatocytes, potentially due to genetic variation in the 
latter61.
While hepatocyte cell lines are effective in predicting the metabolism and elimination of 
some drugs, their overall sensitivity to detect toxic compounds is lower than primary human 
hepatocytes (13% for HepaRG compared to 44% for PHHs)52. Further, being derived from a 
single female donor, these cells do not account for genetic variation in drug responses that 
often uncover limiting toxicities in a subset of persons. This limitation is also seen with 
primary hepatocytes, as testing is often performed on a limited number of donors. 
Importantly, since human hepatic cell lines are derived from primary hepatic tumors, they 
may not accurately represent normal cellular responses. These weakness ultimately require 
the use of complementary approaches (i.e. normal primary cells)23.
Induced and Embryonic Pluripotent Stem Cells (iPSC and ESC)
Stem cells are defined as cells capable of self-renewal and differentiation into mature cells of 
a particular tissue type62. Stem cells encompass both those derived from blastocysts (ESC) 
and also those derived from mature cells through reprogramming (iPSC) using viral vectors, 
Cre-lox expression cassettes, or mRNA/miRNA transfection63. While iPSC generation and 
differentiation is time consuming, it allows for an easily sharable cell population with 
theoretically limitless growth potential that can mimic preliminary clinical trials in vitro, 
hopefully improving the success in subsequent human studies.
Many protocols demonstrate differentiation of iPSC64,65 or ESC66–68 into hepatocyte-like 
cells. Protocols that try to replicate liver embryogenesis can achieve hepatocyte-like cell 
yields of up to 80%68. Additionally, the expression of microRNAs (mir), specifically 
mir-122, during the differentiation process can further improve hepatocyte fidelity69. 
However, many differentiation protocols result in hepatocytes that express immature markers 
(e.g. alpha-feto protein; AFP), secrete less albumin, and exhibit dramatically reduced 
CYP450 activity than primary human hepatocytes70–72. Indeed, hepatocyte-like cells 
differentiated from iPSC using multiple sources and two different protocols demonstrated a 
phenotype akin to fetal hepatocytes73.
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An advantage of iPSCs is the potential to study a broad spectrum of hepatocyte lines with 
different genetic, epigenetic backgrounds71,73 and disease backgrounds. Additionally, iPSCs 
exhibit sensitivity comparable to primary human hepatocytes for detecting drugs that cause 
drug induced liver injury (65% vs 70%)74. While a promising technology, current iPSC 
technical limitations include epigenetic memory, genomic instability, state of maturation to 
adult cells and variability among cell lines. Strategies to address these weaknesses include 
using small molecule treatment, avoiding targeting p53 during reprograming, and use of 
multiple iPSCs from different genetic backgrounds, respectively75. Namely, platforms aimed 
to analyze the influence of small molecules on hepatocyte expansion and differentiation of 
iPSCs to mature hepatocytes have shown promising results76. However, a steady supply of 
hepatocyte-like cells derived from iPSC is often not available to many researchers, which 
limits consistent use to labs with experience in their differentiation. Encouragingly, some 
companies are starting to commercialize iPSC-derived hepatocytes.
Non-parenchymal Cells (NPCs)
The NPC component of the liver is critical to recreating physiologic liver functioning and 
response to injurious stimuli. As such, inclusion of NPCs is desirable to replicate 
metabolism and signaling pathways observed in vivo. Addition of NPCs in hepatic culture 
systems has shown to alter signaling networks present in the microenvironment, enhance 
hepatocyte synthetic functions, prevent hepatocyte de-differentiation in culture, and enhance 
hepatocyte metabolic response to drug treatment1,77,78. Both primary and immortalized cell 
types are available and will be discussed below.
Primary NPCs are isolated in a similar manner to primary hepatocytes, by liver enzymatic 
perfusion. These cells can either be harvested alone or simultaneously with primary 
hepatocytes. When harvested alone, the NPCs of the liver can be enriched, at the expense of 
hepatocyte recovery, by using a pronase-collagenase perfusion method79,80. For isolating 
both cell components, collagenase perfusion followed by density centrifugation are used to 
collect and separate the hepatocytes from the NPCs, respectively. Several methods have been 
used to purify the NPCs, which include iodixanol or percol density gradients and magnetic 
activated cell sorting81–83. Importantly, the disease state of the human donor tissue can 
greatly influence the quality and quantity of cells obtained84,85. To avoid the need for donor 
tissue, others have demonstrated generation of NPCs from human iPSCs86.
While primary NPCs are the most effective at reproducing the microenvironment seen 
physiologically, their main disadvantages are non-specific activation and availability. Using 
primary NPCs requires having surgical specimens. Cryopreserved NPCs can be purchased 
commercially either as a collective or for specific NPC types. Due to the high cost of 
primary cells, various cell lines or alternative cell types have been employed in co-cultures 
with hepatocytes to provide similar trophic signals as primary NPCs. The next several 
sections will illustrate approaches to incorporate each NPC type into hepatic culture 
systems.
Endothelial Cells—Liver sinusoidal endothelial cells (LSECs) are a unique endothelial 
cell type displaying abundant fenestrations, high endocytotic ability, and ability to provide 
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ideal trophic support to hepatocytes. These cells are often unstable in vitro87–90 and are 
difficult to cryopreserve91. As such, some groups have instead used human umbilical vein 
endothelial cells (HUVECs) that, in co-culture with hepatocytes, improve hepatocyte 
specific function, such as CYP450 activity and albumin synthesis92–94. However, as 
HUVECs are a unique cell type that lack appreciable levels of key cell surface receptors 
CXCR395 and EGFR96, other primary human endothelial cells have been employed with 
variable results94,97.
Immortalized endothelial cell lines have also been used in hepatocyte co-culture. HMEC-1 
(human foreskin endothelium) cells have been shown to enhance hepatocyte albumin 
secretion98 and can provide inflammatory cues that affect both the hepatocytes as well as 
metastatic cancer cells99. TMNK-1 cells are an immortalized LSEC cell line that has been 
used in hepatocyte co-culture to investigate paracrine signaling100, influence on cancer cell 
phenotype99, and promote hepatocyte-specific functions in ESC-derived hepatocytes101. 
However, immortalized LSECs phenotypically resemble activated endothelial cells 
implicated in pathologic vessel formation in chronic liver disease102, and may not emulate 
normal physiology, in particular due to their lack of fenestrations.
Kupffer Cells—KCs are implicated in host defense and are important producers of 
cytokines in inflammatory responses and liver diseases. Immortalized KCs have been 
generated in mouse and rat103, but not human. THP-1 monocytes have been differentiated 
into macrophages and used in co-culture applications with both primary hepatocytes and 
human hepatic cell lines. Inflammatory responses were noticed in hepatocytes as a result of 
macrophage-secreted products104 and direct co-culture105. To demonstrate the importance of 
KC inclusion in hepatocyte cultures, LPS stimulation of a primary hepatocyte and KC 
perfusion co-culture system demonstrated no effect on hydrocortisone metabolism, similar 
to that seen clinically106. However, immortalized KCs or activated macrophage cell lines do 
not replicate physiologic KC behavior. KCs are typically quiescent and tolerogenic due to 
high basal expression of TGFβ and PD1 and expression of IL-10 upon LPS stimulation107. 
As such, alternatives to primary KCs may promote more inflammatory-related changes than 
seen in vivo. Of benefit to labs without access to fresh primary cells, cryopreserved KC are 
commercially available for use.
Stellate Cells—Hepatic stellate cells (HSCs) are important cells for the storage of 
retinoids and other lipids and are implicated in hepatocyte proliferation after partial 
hepatectomy, hepatic fibrosis, and portal hypertension. Freshly isolated primary HSCs 
quickly activate when cultured on plastic108 and their gene expression in vitro does not fully 
reproduce that observed in vivo109. HSC quiescence can be preserved by culturing on 
laminin-rich gels or in suspension on a non-adherent surface110. Several immortalized HSC 
lines exist for study, including hTERT-HSC, GREF-X, LI90, TWNT-1 and more recently, 
LX-1 and LX-2. However, only the LX-2 cell line can be maintained in serum-free media 
and transfected with relatively high efficiency (30%)111. Importantly, while immortalized 
cell lines express many of the same markers as primary HSCs, their response to stimuli and 
basal level of activation differ from that observed in vivo112. Co-culture of HSCs with 
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hepatocytes has been used to maintain hepatocyte differentiation in vitro by cell contact 
mediated signals and transfer of lipids113.
NPC Considerations
It is clear that including NPCs in culture systems influences hepatocyte functions and the 
tissue microenvironment. ECs can enhance albumin synthesis and CYP450 activity in co-
culture with hepatocytes. KCs can elicit inflammatory changes in response to stimuli that 
resemble those seen in vivo. Finally, HSCs are important for storing lipids that can be 
utilized by the hepatocytes and preserving hepatocyte differentiation. While primary non-
parenchymal cells are the gold standard, they are difficult to obtain in sufficient numbers. 
NPC yield is low when isolated concurrently with hepatocytes and subsequent purification 
steps can alter NPC function. Several immortalized cell lines can serve comparable (though 
not equivalent) roles for each NPC type, and also offer the benefits of being easily 
distributable and homogeneous.
Engineered Culture Systems
The overarching goal of all liver culture systems is to provide either a high throughput, low 
cost, easy to operate, and reliable system that recapitulates a reasonable fraction of human 
physiology, or a medium to low throughput system that reliably recapitulates liver structure 
and function (liver biomimetic). This depends on the ability of the system to generate an 
environment that reflects the in vivo phenotype of the hepatocytes and NPCs, which is 
highly dependent on both chemical and mechanical cues. A critical issue with routine 2D 
primary human hepatocyte culture systems is that hepatocyte functionality rapidly declines 
within days114. To overcome this, hepatocytes have been cultured using the collagen-
sandwich method. This involves seeding a monolayer of hepatocytes on a gelled layer of rat 
tail collagen and overlaying another gelled collagen layer on top. This culture method allows 
hepatocytes to maintain synthetic function (as determined by albumin mRNA) for at least six 
weeks115. However, collagen sandwich cultures do not replicate the complex multi-cellular 
nature of the liver and does not incorporate fluid flow, which is important for preserving in 
vivo hepatocyte function116. Several of the most recent engineering advances to improve 
hepatocyte function and viability in culture will be discussed in this review. These systems 
are demarcated into the following categories: 2D Micro-Patterned Systems, 3D Spheroid 
Culture Systems, and Perfusion Culture Systems. For a comprehensive review of all 
advancements made in the realm of hepatocyte culture, the reader is referred to other 
references25,117,118.
Non-Perfusion Systems
Both static and perfusion systems exist for hepatocyte culture. Static culture systems include 
2D micro-patterned systems and 3D spheroid culture systems. A summary of the properties 
of these systems can be found in Table 2.
2D Micro-Patterned Systems—The use of 2D micro-patterned culture systems are an 
improvement upon standard sandwich culture as they fine-tune tissue architecture by 
controlling the size, geometry, and functionality of culture chambers. One commercialized 
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system, HepatoPac™ by Hepregen, Corp. consists of micro-patterned 2D plates seeded with 
either rat or human hepatocytes and 3T3-J2 stromal cells. Cultures maintain hepatocyte 
specific functions for 4–6 weeks119–121, notably albumin and urea secretion, phase I/II 
metabolism, and formation of canalicular networks. Publications have also reported 
sensitivities of 66% and 100% for corroborating hepatotoxins when tested with one or at 
least two cell donors, respectively120. The extended hepatocyte functionality may allow for 
accurate predictions of in vivo drug transporter activity122. Additionally, this system can be 
used to model CYP450 enzyme induction121,123. However, this system’s low throughput 
make it less suitable than traditional monolayer culture for toxicity screening studies124.
Similar systems have used micro-patterned hepatocyte islands to enhance hepatocyte 
functioning in 2D culture. For example, Cho and colleagues used polydimethylsiloxane 
(PDMS) stencils to co-culture rat hepatocytes and 3T3 fibroblasts and demonstrated 
enhanced hepatocyte functions when co-cultured in a layered format (hepatocytes seeded on 
an island of fibroblasts) as compared to a co-planar format125. Ware and colleagues used 
micro-patterned hepatocyte-murine fibroblast co-cultures to predict hepatotoxicity using 
both primary human hepatocytes and iPSC-derived hepatocyte-like cells74. However, these 
systems do not take advantage of the positive influence of LSECs on hepatocyte functions, 
as previously shown with hepatocyte co-culture with HUVECs126.
Since these systems involve a monolayer of cells, they are amenable to high content image 
analysis without confocal optics. However, these systems have not been fully characterized 
for co-culture with liver-specific NPCs and are patterned using rat tail collagen I rather than 
liver specific matrix proteins23. Previous studies have shown that culturing hepatocytes on 
liver-specific ECM leads to higher attachment efficiency and lower expression of the 
dedifferentiation markers vimentin and cytokeratin 18127. Moreover, supplementation of 
liver-specific ECM digests in hepatocyte cultures showed improved albumin synthesis and 
CYP450 activity128,129. Enhanced albumin secretion and cellular connectivity is also 
observed with less stiff culture substrates, such as heparin gels, with the least physiological 
morphology observed on collagen coated glass130. These findings suggest culture materials 
that mimic physiologic liver extracellular matrix promote maintenance of in vivo hepatocyte 
functions.
3D Spheroid Culture Systems—Three dimensional culture systems add an additional 
layer of complexity by more accurately representing the tissue architecture of a whole liver. 
Micro-patterning and functionalizing surfaces can facilitate the formation of 3D hepatocyte 
spheroids. For example, Fukuda and colleagues micro-patterned cylindrical culture wells 
with collagen and polyethyleneglycol, which facilitated rat hepatocyte spheroid formation. 
These spheroids demonstrated enhanced albumin secretion and ammonia detoxification 
compared to monolayer culture for up to 14 days in culture131. They also used a photo-
crosslinkable chitosan hydrogel to incorporate 3T3 fibroblasts into their spheroids132.
Liu et al micro-patterned electrospun fibrous mats for the co-culture of rat hepatocytes, 
HUVECs, and 3T3 fibroblasts lasting up to 15 days93. They observed the formation of 
hepatocyte spheroids and noted co-culture with both fibroblasts and endothelial cells 
enhanced albumin secretion, urea synthesis, and CYP450 expression as compared to 
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monoculture or co-culture with either fibroblasts or endothelial cells alone. While this 
system incorporates all three cell types on the same culture surface, each cell type is seeded 
in a specific area, limiting direct contact but allowing paracrine communication93.
Alternatively, primary rat hepatocytes and 3T3 fibroblasts can initially be co-cultured on 2D 
micro-patterned surfaces and the resulting cell aggregates detached and encapsulated in PEG 
to form 3D spheroids133. These spheroids are capable of showing dose-dependent 
acetaminophen toxicity responses, as well as CYP450 induction by model compounds, such 
as rifampin and phenobarbital. Additionally, the small size of these spheroids (~100µm) 
prevents the formation of a necrotic core. However, this system has not yet been 
characterized using human hepatocytes.
Bell and colleagues have generated spheroids from primary human cryopreserved 
hepatocytes and NPCs that demonstrate preserved metabolic function and viability up to five 
weeks in culture134. Beneficially, this system uses all human cells, is highly scalable (made 
in 96 well plates), and demonstrates long term response to hepatotoxins. However, the cell-
to-media ratio is quite low, which may reduce the impact of paracrine factors secreted by the 
spheroids.
There are two 3D spheroid systems commercially available. First, RegeneTox™ marketed 
by Regenemed Inc. allows for the co-culture of NPCs and hepatocytes through use of a 
transwell insert. NPCs are seeded above two interconnected nylon scaffolds and cultured for 
a week prior to hepatocyte isolation and seeding. The media are changed three times a week 
and the co-cultures can last more than three months in the system, as demonstrated by 
albumin, urea, transferrin, and fibrinogen secretion, and stable CYP1A1, 3A4, and 2C9 
activity. Moreover, the liver tissue was responsive to inflammatory stimuli by releasing 
mediators such as TNFα and IL-8135. However, this system is relatively low throughput (24-
well plate equivalent) and utilizes a culture surface orders of magnitude stiffer than native 
liver tissue.
GravityTRAP™ marketed by InSphero AG uses a hanging drop platform to seed cells in a 
concentrated suspension to grow liver tissue in 3D. These tissues can be transferred into a 
specialized 96-well plate for culture and analysis, remaining viable for at least 4 weeks. 
Spheroids demonstrate robust CYP3A4 expression and albumin production compared to 2D 
cultures. Spheroid size is highly reproducible but may be time consuming without 
automation. Additionally, spheroid size is limited, as spheroids larger than 200µm develop 
central necrosis due to hypoxia136.
While the dimensionality of these systems allow for more complex intercellular 
communication than 2D culture systems, they do not incorporate flow, which is known to be 
important for maintaining liver-cell specific functions.
Perfusion Culture Systems
Perfusion culture systems allow for the incorporation of physiological “blood” flow (media), 
which is an important factor for hepatocyte detoxification of drugs137 and establishment of 
the physiological oxygen and chemical gradients. Such systems will be grouped by their size 
Beckwitt et al. Page 11
Exp Cell Res. Author manuscript; available in PMC 2019 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
(both volume and cell number), designated as either macroscale or microscale. A summary 
of the properties of the discussed systems can be found in Table 3.
Macroscale—A few groups have applied large scale perfusion bioreactor devices to the 
culture of hepatocyte spheroids for drug discovery applications. For example, Tostoes and 
colleagues demonstrated the culture of primary human hepatocyte spheroids in a spinning 
perfusion bioreactor for up to 3–4 weeks138. The working volume was 300mL and 20% of 
this was replaced daily through medium perfusion. They demonstrated CYP450 induction 
and the metabolism of a model substrate, 7-methoxycoumarin. While albumin synthesis 
increased and stabilized over the culture period, urea synthesis significantly decreased with 
culture, likely due to spheroid hypoxia. Additionally, this culture system has only been 
tested for hepatocyte monoculture.
Another system uses a radial flow bioreactor (RFB), where the bed of matrix housing cells 
separates the media inlet and outlet, which facilitates nutrient and oxygen diffusion across 
the tissue. Park and colleagues co-cultured rat hepatocytes and 3T3-J2 fibroblasts on a series 
of stacked glass substrates, with microfabricated grooves and a collagen coating, to improve 
oxygen delivery to the tissue139. However, while RFBs culture large number of hepatocytes 
(2–5×107), the high flow rates used cause loss of hepatic-specific functions after a few days 
due to unphysiological shear stresses139.
Vinci and colleagues cultured primary human hepatocytes on coverslips for 7 days then 
transferred the coverslips into either their multichamber bioreactor or a new dish for 
continued static culture. They found that the expression of metabolic (CYP450) and 
transport (OATP, MDR1) genes were much higher under perfusion conditions and that 
higher flow rates affected this enhanced expression140. The use of primary human 
hepatocytes makes this system amenable to the investigation of human-specific drug 
interactions. However, the working volume (5mL) is quite large compared to the cell seeding 
number (200k), which reduces the influence of secreted factors.
While macroscale perfusion culture systems allow for the influences of shear stress and 
nutrient supply on drug detoxification to be extrapolated, they carry several weaknesses. 
First, the number of cells required is substantially higher than smaller-scale culture systems, 
which may prove challenging given the limited availability of hepatocytes. Second, the 
media volume to cell volume ratio is much higher than is seen in vivo. Third, many of these 
systems replace the circulating media with fresh media on a continuous basis. As such, these 
systems may demonstrate reduced signaling from soluble factors released by the hepatic 
tissue.
Microscale—In contrast to macroscale (5–300mL) perfusion culture systems, the use of 
microscale (0.1–3mL) systems allows for higher cell-to-media volume ratios, which 
approach those seen in vivo. The LiverChip by CNBio Innovations (originally Zyoxel) 
models the liver tissue with a perfusion system on a larger volume scale than most micro-
perfusion systems (1.6mL)2,77,141,142. Earlier generations of this system utilized alternative 
well geometry143,144. Hepatocytes and a full complement of donor matched NPCs are 
seeded on polystyrene (mechanically stiff) scaffolds at a 1:1 ratio. Fluid flow is driven by 
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pneumatic pumps at a rate of 60 µL/min through the scaffolds, providing direct, but 
physiologically representative shear stresses and oxygen gradients on the resident tissue cells 
(Figure 1B). Tissues are established and remain functional up to one month, as measured by 
blood urea nitrogen levels, fibrinogen, alpha-1 antitrypsin (A1AT), and CYP450 activity. 
The culture chamber allows for a 3D hepatic tissue to form, which provides an advantage 
over 2D culture systems by facilitating cell junction formation. This culture system has been 
used to study metastasis of cancer cells in the context of the liver 
microenvironment2,77,141,142 and probe the influence of LPS on hydrocortisone 
metabolism145. This system offers a unique opportunity to study cancer drug efficacy and 
hepatotoxic effects in a single system. However, there is currently no effective way to 
physically monitor tissue formation during the culture period.
Choucha-Snouber and colleagues designed a liver biochip to investigate metabolic responses 
to the anticancer drug flutamide146. Their chip is fabricated from PDMS and contains 
fibronectin-coated microstructures for cell seeding. HepG2/C3a cells are seeded in the 
system and kept in culture for a total of 48 hours, 24 hours of which is for perfusion and 
drug treatment. In comparison to the LiverChip, this system uses a lower flow rate of 10µL/
min. The low volume of the biochip (40µL) is desirable to achieve a physiologic ratio of 
media supply to cell volume. However, this system has not tested co-culture with NPCs. 
Additionally, using PDMS as the fabrication substrate allows for gasses to readily equilibrate 
between the external environment and the cell culture chamber, which may limit modeling 
of a physiologically hypoxic liver microenvironment. Additionally, small hydrophobic 
compounds adsorb to PDMS, which limits the drugs this system can accurately assess 
without extensive calibration and testing. This design was extended to investigate kidney-
liver co-culture systems147.
Hoffmann and colleagues designed a hollow-fiber based microscale perfusion culture 
system, with a volume of 0.5mL148. A unique feature of this system is the incorporation of 
three different supply channels to the cultured tissue – two media circuits and one gas 
circuit. The authors demonstrate robust tissue formation, which includes NPCs. Moreover, 
NPCs were noted to form vascular-like structures. While the culture volume is low, the flow 
rate and fresh media replenishment rate are quite high in comparison (3mL/min and 0.5mL/
hour respectively). This may prove a limiting factor for analyzing long-term effects of 
secreted factors. Additionally, the expression and activity of several CYP450 (3A4 and 2B6) 
isoforms decreases dramatically between days 3 and 10 of culture148. Since 50% of 
currently tested drugs are metabolized by CYP3A4149, the decrease in its activity over the 
culture period may make this system not suitable for long term toxicity or metabolic assays.
CellAsic designed a hepatic sinusoid cord-like culture system, in which a central cord of 
cells is enveloped by a fluid transport channel. Communication between the cells and fluid 
channel was accomplished by small (1µm by 2µm) canals, limiting transport to diffusion. 
The system is primed with fluid and cells are subsequently seeded. After cell seeding, the 
chip is placed in the incubator on an incline to facilitate gravity-driven continuous flow, at 
rates of 10–20nL/min, to supply the tissue. The system can maintain hepatocytes for over 1 
week, as determined by albumin secretion, and exhibit dose-dependent hepatotoxicity of 
diclofenac as seen in vivo150,151. Thirty two independent culture systems can be run 
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simultaneously on a device the size of a 96-well plate. While this system generates 3D 
tissue, an improvement over 2D culture systems, it has not been investigated for culture 
periods longer than 7 days.
HµREL® biochips by Hurel Corp. allow up to 8 microfluidic circuits to operate in 
parallel152. These chips contain two cell culture compartments connected in series, one of 
which was designed to house liver tissue. Cells are seeded onto the polystyrene biochip 
either in monoculture or co-culture, using human hepatocytes and NPCs. Flow was 
generated by use of a peristaltic pump with a flow rate of 4.5µL/min/chip. Hepatocyte co-
cultures in the system subjected to flow demonstrated increased metabolic activity when 
compared to static monocultures or co-cultures and remained viable for up to 6 days116. One 
advantage of this system is that the HµREL tubing exhibits limited adsorption of 
hydrophobic drug molecules. Additionally, the polystyrene housing reduces gas permeability 
of the device, facilitating formation of a hypoxic microenvironment. However, the tissues 
formed in this system are not 3D and the maximum culture period is limited compared to 
other systems. Moreover, CYP450 isoforms exhibit varying activities in the system – while 
CYP3A4 activity increases over the 6 day culture duration, CYP2D6 activity decreases after 
2 days of culture116.
Finally, the liver acinus microphysiology system (LAMPS) is a microfluidic platform to 
investigate hepatic physiology, drug safety, and disease models8 that evolved from the first 
generation liver MPS (SQL-SAL)153. The LAMPS incorporates either fresh or 
cryopreserved human hepatocytes, as well as a full complement of non-parenchymal cells: 
human endothelial (primary or TMNK-1), immune (THP-1 or U937), and stellate (LX-2) 
cells in a Nortis, Inc microfluidic device. A porcine liver extracellular matrix (LECM), ca. 
10µm thick, is layered between the endothelial cells and the hepatocytes. Approximately 
20% of the hepatocytes and stellate cells contain fluorescent biosensors that measure 
apoptosis and reactive oxygen species for real-time fluorescence readouts154, along with 
analysis of the secretome and metabolic activity. Distinct zone 1 and zone 3 
microenvironments are created that allow the direct determination of zone-specific 
physiological and disease functions155. This system is viable for at least 28 days under 
continuous perfusion flow and exhibits concentration- and time-dependent toxicity profiles 
to drugs (e.g. troglitazone) in a similar manner to that seen clinically156. Structurally, the 
endothelial cells are separated from the hepatocytes by a biomimetic of the Space of Disse 
forming a three-dimensional layer of cells and LECM. The immune cells permit the system 
to be LPS responsive, releasing TNFα upon stimulation and in combination with some drugs 
causes immune-mediated hepatotoxicity. Moreover, the LX-2 cells can be activated in 
response to methotrexate treatment, resulting in the expression of smooth muscle actin 
(SMA) and the production of collagen 1A2, reflecting a fibrosis phenotype. Most 
importantly, this system is amenable to real-time transmitted light and fluorescence imaging, 
allowing for investigating toxicity kinetics and disease progression.
The platform is continually being evolved to replace the NPCs with either primary human 
cells or iPSC-derived cells, since the use of immortalized NPCs may not reflect full 
physiological capabilities. This platform contains PDMS which requires the presence of 
carrier proteins for hydrophobic drugs and pre-measurement of the loss of drugs to the 
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device before making any interpretations157. Finally, the media in this system is not 
recirculated in the current format. However, the small volumes and low flow rates allow the 
detection of paracrine signaling mediators secreted by the cells, although there are other 
advantages to having the media recirculated (see above).
Conclusions and Future Directions
Advanced liver culture systems hold the potential to transform drug discovery and 
development, through more accurate modeling of human in vivo pharmacokinetics and 
pharmacodynamics, as well as understanding mechanisms of disease progression and 
toxicity. Several factors affect the accuracy of these model systems in predicting 
pharmaceutical toxicity. The cells used in the culture system and the culture surface (e.g. 
plastic, hydrogel) allow for modeling cell-cell and cell-ECM interactions respectively. 
Systems that include media flow (“blood flow”) provide mechanical stimuli that benefit 
tissue function. Inclusion of cells derived from human tissues allows for human-specific 
pathways to be modeled. Special attention should be paid to the use of primary versus 
immortalized cells, as the latter may elicit signals not seen in physiologic conditions. The 
use of animal cells instead of human cells may encounter similar intractable weaknesses. 
Importantly, the expression levels of CYP450 isoforms and drug transporters over the 
culture period may influence toxicity predictions.
Future directions for improving these systems include incorporating lentiviral-induced 
fluorescent biosensors for an automated readout of various cellular functions154 and finer 
architectural control of liver microstructure. Importantly, the ability to image the devices in 
real time is highly advantageous. Fabrication of devices using materials other than PDMS – 
which adsorbs hydrophobic molecules and biologics – will improve the utility of these 
devices as pharmacokinetic models for drug discovery. Moreover, procurement of a 
universal, readily available cell source (potentially iPSC-derived hepatocytes) will improve 
the ease with which these systems are used for drug characterization studies. Networking of 
additional organ chips, such as gut and kidney, will contribute additional signals to the liver 
tissue, allow for modeling of drug absorption, and disposition after hepatic metabolism. 
Finally, further development and usage of quantitative systems pharmacology as a new 
paradigm in drug discovery and development involving the integration and iteration of 
experimental and computational models, in parallel with advanced culture systems will 
facilitate complex data analysis and may allow for predictive models to be generated158,159.
It is hoped that the development of validated human experimental model systems can be 
used in place of animal models to improve preclinical drug selection. By implementing more 
accurate human experimental model systems, it is expected that there will be increased 
efficacy and safety in clinical trials leading to improved therapeutics at a lower cost.
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Figure 1. 
(A) The architecture of the hepatic sinusoid. Blood enters the portal triad region of the liver 
through a hepatic arteriole and portal venule and traverses the hepatic sinusoid to the central 
vein, whereby it is drained into the larger hepatic central veins. The sinusoidal endothelial 
cells mediate blood flow and are fenestrated to allow rapid diffusion of nutrients, signaling 
factors, and drug compounds. The hepatocytes compose the parenchyma of the liver and sit 
deep to the endothelium. The hepatic stellate cells reside in the Space of Disse, a zone 
between the endothelium and hepatocytes. Finally, the Kupffer cells line the inside of the 
sinusoid and mediate antigen sensing and intercellular communication. (B) A schematic of 
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the three dimensional liver tissues as presented within the LiverChip, that are subject to fluid 
flow in micro-scale pores of a scaffold, which facilitates shear stresses and establishment of 
a physiological oxygen gradient.
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